Currently, the first-line therapy for UTUC includes platinum-based chemotherapy, while anti-Programmed Death 1 (PD-1) or Programmed Death Ligand 1 (PD-L1) inhibitor is the second-line therapy for these patients [3]. This evidence concerns the gene CD274 and renal pelvis/ureter urothelial carcinoma.